$10.05
2.24% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US86150R1077
Symbol
STOK

Stoke Therapeutics Inc Stock price

$10.05
+1.44 16.72% 1M
-1.26 11.14% 6M
-0.98 8.88% YTD
-6.05 37.58% 1Y
-4.08 28.87% 3Y
-18.45 64.74% 5Y
-7.95 44.17% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.22 2.24%
ISIN
US86150R1077
Symbol
STOK

Key metrics

Market capitalization $548.70m
Enterprise Value $195.51m
P/E (TTM) P/E ratio 12.77
EV/FCF (TTM) EV/FCF 2.83
EV/Sales (TTM) EV/Sales 1.02
P/S ratio (TTM) P/S ratio 2.87
P/B ratio (TTM) P/B ratio 1.57
Revenue growth (TTM) Revenue growth 2,333.50%
Revenue (TTM) Revenue $190.91m
EBIT (operating result TTM) EBIT $38.24m
Free Cash Flow (TTM) Free Cash Flow $69.20m
Cash position $357.40m
EPS (TTM) EPS $0.79
P/E forward negative
P/S forward 3.19
EV/Sales forward 1.14
Short interest 28.46%
Show more

Is Stoke Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Stoke Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Stoke Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Stoke Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Stoke Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
191 191
2,332% 2,332%
100%
- Direct Costs 4.41 4.41
6% 6%
2%
187 187
5,821% 5,821%
98%
- Selling and Administrative Expenses 47 47
35% 35%
24%
- Research and Development Expense 97 97
18% 18%
51%
43 43
137% 137%
22%
- Depreciation and Amortization 4.41 4.41
6% 6%
2%
EBIT (Operating Income) EBIT 38 38
132% 132%
20%
Net Profit 50 50
146% 146%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Stoke Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stoke Therapeutics Inc Stock News

Neutral
Business Wire
8 days ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the ...
Neutral
Business Wire
about 2 months ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Execut...
Negative
Investopedia
2 months ago
Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.
More Stoke Therapeutics Inc News

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Head office United States
CEO Ian Smith
Employees 128
Founded 2014
Website www.stoketherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today